RSV disease in infants and young children: Can we see a brighter future?

References

• Azzari C, Baraldi E, Bonanni P, Bozzola E, Coscia A, Lanari M, Manzoni P, Mazzone T, Sandri F, Checcucci Lisi G, et al. Epidemiology and prevention of respiratory syncytial virus infections in children in Italy. Ital J Pediatr. 2021;47(1):1. doi:10.1186/s13052-021-01148-8.
   PubMed Web of Science ®Google Scholar
• Pellegrinelli L, Galli C, Bubba L, Cereda D, Anselmi G, Binda S, Gramegna M, Pariani E. Respiratory syncytial virus in influenza-like illness cases: epidemiology and molecular analyses of four consecutive winter seasons (2014-2015/2017-2018) in Lombardy (Northern Italy). J Med Virol. 2020;92(12):2999–14. doi:10.1002/jmv.25917.
   Web of Science ®Google Scholar
• Shi T, Denouel A, Tietjen AK, Campbell I, Moran E, Li X, Campbell H, Demont C, Nyawanda BO, Chu HY, et al. Global disease burden estimates of respiratory syncytial virus–associated acute respiratory infection in older adults in 2015: a systematic review and meta-analysis. J Infect Dis. 2021;222(Supplement_7):S577–83. doi:10.1093/infdis/jiz059.
   Google Scholar
• Openshaw PJM, Chiu C, Culley FJ, Johansson C. Protective and harmful immunity to RSV infection. Annu Rev Immunol. [Internet]. 2017;35(1):501–32. doi:10.1146/annurev-immunol-.
   PubMedGoogle Scholar
• Andeweg SP, Schepp RM, van de Kassteele J, Mollema L, Berbers GAM, van Boven M. Population-Based serology reveals risk factors for RSV infection in children younger than 5 years. Sci Rep. 2021;11(1):8953. doi:10.1038/s41598-021-88524-w.
   PubMed Web of Science ®Google Scholar
• Mazur NI, Martinón-Torres F, Baraldi E, Fauroux B, Greenough A, Heikkinen T, Manzoni P, Mejias A, Nair H, Papadopoulos NG, et al. Lower respiratory tract infection caused by respiratory syncytial virus: current management and new therapeutics. Lancet Respir Med. 2015;3(11):888–900. doi:10.1016/S2213-2600(15)00255-6.
   PubMed Web of Science ®Google Scholar
• Nair H, Theodoratou E, Rudan I, Nokes DJ, Ngama HM, Munywoki PK, Dherani M, Nair H, Nokes DJ, Gessner BD, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet. [Internet]. 2010;375(9725):1545–55. www.thelancet.com.
   PubMed Web of Science ®Google Scholar
• Demont C, Petrica N, Bardoulat I, Duret S, Watier L, Chosidow A, Lorrot M, Kieffer A, Lemaitre M. Economic and disease burden of RSV-associated hospitalizations in young children in France, from 2010 through 2018. BMC Infect Dis. 2021;21(1):730. doi:10.1186/s12879-021-06399-8.
   PubMed Web of Science ®Google Scholar
• Kramer R, Duclos A, Lina B, Casalegno JS. Cost and burden of RSV related hospitalisation from 2012 to 2017 in the first year of life in Lyon, France. Vaccine. 2018;36(45):6591–93. doi:10.1016/j.vaccine.2018.09.029.
   PubMed Web of Science ®Google Scholar
• Brady MT, Byington CL, Davies HD, Edwards KM, Jackson MA, Maldonado YA, Murray DL, Orenstein WA, Rathore MH, Sawyer MH. American Academy of Pediatrics, Committee on Infectious Diseases and Bronchiolitis Guidelines Committee. Updated guidance for Palivizumab Prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics. 2014;134(2):e620–38. doi:10.1542/peds.2014-1666.
   PubMedGoogle Scholar
• Meissner HC, Ingelfinger JR. Viral bronchiolitis in children. N Engl J Med. 2016;374(1):62–72. doi:10.1056/NEJMra1413456.
   PubMed Web of Science ®Google Scholar
• Greenough A, Cox S, Alexander J, Lenney W, Turnbull F, Burgess S, Chetcuti AJ, Shaw NJ, Woods A, Boorman J, et al. Health care utilisation of infants with chronic lung disease, related to hospitalisation for RSV infection. Arch Dis Child. 2001;85(6):463–68. doi:10.1136/adc.85.6.463.
   PubMed Web of Science ®Google Scholar
• Parrott RH, Kim HW, Arrobio JO, Hodes DS, Murphy BR, Brandt CD, Camargo E, Chanock RM. Epidemiology of respiratory syncytial virus infection in Washington, D.C. Am J Epidemiol. 1973;98(4):289–300. doi:10.1093/oxfordjournals.aje.a121558.
   PubMed Web of Science ®Google Scholar
• Meissner HC, Long SS. Committee on Infectious Diseases and Committee on Fetus and Newborn. Revised indications for the use of Palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Pediatrics. 2003;112(6):1447–52. doi:10.1542/peds.112.6.1447.
   PubMedGoogle Scholar
• Blanken MO, Rovers MM, Molenaar JM, Winkler-Seinstra PL, Meijer A, Kimpen JLL, Bont L. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants. N Engl J Med. 2013;368(19):1791–99. doi:10.1056/NEJMoa1211917.
   PubMed Web of Science ®Google Scholar
• Hall CB. Respiratory syncytial virus and parainfluenza virus. N Engl J Med [Internet]. 2001;344(25):1917–28. www.nejm.org.
   PubMed Web of Science ®Google Scholar
• Hall CB, Weinberg GA, Iwane MK, Blumkin AK, Edwards KM, Staat MA, Auinger P, Griffin MR, Poehling KA, Erdman D, et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med. 2009;360(6):588–98. doi:10.1056/NEJMoa0804877.
   PubMed Web of Science ®Google Scholar
• Sigurs N, Gustafsson PM, Bjarnason R, Lundberg F, Schmidt S, Sigurbergsson F, Kjellman B. Severe respiratory syncytial virus bronchiolitis in infancy and asthma and allergy at age 13. Am J Respir Crit Care Med. 2005;171(2):137–41. doi:10.1164/rccm.200406-730OC.
   PubMed Web of Science ®Google Scholar
• Baraldi E, Bonadies L, Manzoni P . Evidence on the link between respiratory syncytial virus infection in early life and chronic obstructive lung diseases. Am J Perinatol. 2020;37(S 02):S26–30.
   PubMedGoogle Scholar
• Turnham H, Agbeko RS, Furness J, Pappachan J, Sutcliffe AG, Ramnarayan P. Non-Invasive respiratory support for infants with bronchiolitis: a national survey of practice. BMC Pediatr. 2017;17(1):20. doi:10.1186/s12887-017-0785-0.
   PubMedGoogle Scholar
• Baraldi E, Lanari M, Manzoni P, Rossi GA, Vandini S, Rimini A, Romagnoli C, Colonna P, Biondi A, Biban P, et al. Inter-Society consensus document on treatment and prevention of bronchiolitis in newborns and infants. Ital J Pediatr. 2014;40(1):65. doi:10.1186/1824-7288-40-65.
   PubMedGoogle Scholar
• National Institute for Health and Care Excellence (NICE). Bronchiolitis in children Funding National Institute for Health and Care Excellence Bronchiolitis in children contents [Internet]. London; 2021 [accessed 2021 Dec 20]. www.nice.org.uk/guidance/ng9
   Google Scholar
• Ralston SL, Lieberthal AS, Meissner HC, Alverson BK, Baley JE, Gadomski AM, Johnson DW, Light MJ, Maraqa NF, Mendonca EA, et al. Clinical practice guideline: the diagnosis, management, and prevention of bronchiolitis. Pediatrics. 2014;134(5):e1474–502. doi:10.1542/peds.2014-2742.
   PubMed Web of Science ®Google Scholar
• Florin TA, Plint AC, Zorc JJ. Viral bronchiolitis. The Lancet. 2017;389(10065):211–24. doi:10.1016/S0140-6736(16)30951-5.
   PubMed Web of Science ®Google Scholar
• Giersing BK, Karron RA, Vekemans J, Kaslow DC, Moorthy VS. Meeting report: WHO consultation on Respiratory Syncytial Virus (RSV) vaccine development, Geneva, 25–26 April 2016. Vaccine. 2019;37(50):7355–62. doi:10.1016/j.vaccine.2017.02.068.
   PubMed Web of Science ®Google Scholar
• Ruckwardt TJ, Morabito KM, Graham BS. Immunological lessons from respiratory syncytial virus vaccine development. Immunity. 2019;51(3):429–42. doi:10.1016/j.immuni.2019.08.007.
   PubMed Web of Science ®Google Scholar
• Andabaka T, Nickerson JW, Rojas-Reyes MX, Rueda JD, Bacic Vrca V, Barsic B. Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children. Cochrane Database Syst Rev. 2013 Apr;(4): CD006602. doi:10.1002/14651858.cd006602.pub4.
   PubMed Web of Science ®Google Scholar
• Barbati F, Moriondo M, Pisano L, Calistri E, Lodi L, Ricci S, Giovannini M, Canessa C, Indolfi G, Azzari C. Epidemiology of respiratory syncytial virus-related hospitalization over a 5-year period in Italy: evaluation of seasonality and age distribution before vaccine introduction. Vaccines (Basel). 2020;8(1):15. doi:10.3390/vaccines8010015.
   PubMed Web of Science ®Google Scholar
• Janet S, Broad J, Snape MD. Respiratory syncytial virus seasonality and its implications on prevention strategies. Hum Vaccin Immunother. 2018;14(1):234–44. doi:10.1080/21645515.2017.1403707.
   PubMed Web of Science ®Google Scholar
• Pouwels KB, Bozdemir SE, Yegenoglu S, Celebi S, McIntosh ED, Unal S, Postma MJ, Hacimustafaoglu M, Cormier SA. Potential cost-effectiveness of RSV vaccination of infants and pregnant women in Turkey: an illustration based on bursa data. PLoS ONE. 2016;11(9):e0163567. doi:10.1371/journal.pone.0163567.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Yuan L, Zhang Y, Zhang X, Zheng M, Kyaw MH. Burden of respiratory syncytial virus infections in China: systematic review and meta–analysis. J Glob Health. 2015;5(2). doi:10.7189/jogh.05.020417.
   Web of Science ®Google Scholar
• Pebody R, Moyes J, Hirve S, Campbell H, Jackson S, Moen A, Nair H, Simões EAF, Smith PG, Wairagkar N, et al. Approaches to use the WHO respiratory syncytial virus surveillance platform to estimate disease burden. Influenza Other Respir Viruses. 2020;14(6):615–21. doi:10.1111/irv.12667.
   PubMed Web of Science ®Google Scholar
• Cromer D, Jan Van Hoek A, Newall AT, Pollard AJ, Jit M Articles burden of paediatric respiratory syncytial virus disease and potential effect of different immunisation strategies: a modelling and cost-effectiveness analysis for England [Internet]. 2017. www.thelancet.com/
   Google Scholar
• Olchanski N, Hansen RN, Pope E, D’-Cruz B, Fergie J, Goldstein M, Krilov LR, McLaurin KK, Nabrit-Stephens B, Oster G, et al. Palivizumab prophylaxis for respiratory syncytial virus: examining the evidence around value. Open Forum Infect Dis. 2018;5(3):ofy031. doi:10.1093/ofid/ofy031.
   PubMed Web of Science ®Google Scholar
• Mac S, Sumner A, Duchesne-Belanger S, Stirling R, Tunis M, Sander B. Cost-Effectiveness of Palivizumab for respiratory syncytial virus: a systematic review. Pediatrics. 2019;143(5):20184064. doi:10.1542/peds.2018-4064.
   PubMed Web of Science ®Google Scholar
• Shi T, McAllister DA, O’-Brien KL, Simoes EAF, Madhi SA, Gessner BD, Polack FP, Balsells E, Acacio S, Aguayo C, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet. 2017;390(10098):946–58. doi:10.1016/S0140-6736(17)30938-8.
   PubMed Web of Science ®Google Scholar
• Pitzer VE, Viboud C, Alonso WJ, Wilcox T, Metcalf CJ, Steiner CA, Haynes AK, Grenfell BT, Kaderali L. Environmental drivers of the spatiotemporal dynamics of respiratory syncytial virus in the United States. PLoS Pathog. 2015;11(1):e1004591. doi:10.1371/journal.ppat.1004591.
   PubMed Web of Science ®Google Scholar
• Baker RE, Mahmud AS, Wagner CE, Yang W, Pitzer VE, Viboud C, Vecchi GA, Metcalf CJE, Grenfell BT. Epidemic dynamics of respiratory syncytial virus in current and future climates. Nat Commun. 2019;10(1):5512. doi:10.1038/s41467-019-13562-y.
   PubMedGoogle Scholar
• Weigl JAI, Puppe W, Schmitt HJ. Incidence of respiratory syncytial virus-positive hospitalizations in Germany. Eur J Clin Microbiol Infect Dis. 2001;20(7):0452–9. doi:10.1007/s100960100527.
   PubMed Web of Science ®Google Scholar
• Leader S, Kohlhase K. Respiratory syncytial virus-coded pediatric hospitalizations, 1997 to 1999. Pediatr Infect Dis J. 2002;21(7):629–32. doi:10.1097/00006454-200207000-00005.
   PubMed Web of Science ®Google Scholar
• Leader S, Kohlhase K, Pearlman MH, Williams JV, Engle WA. Recent trends in severe respiratory syncytial virus (RSV) among US infants, 1997 to 2000. J Pediatr. 2003;143(5):S127–32. doi:10.1067/S0022-3476(03)00510-9.
   PubMed Web of Science ®Google Scholar
• Palmer L, Hall CB, Katkin JP, Shi N, Masaquel AS, McLaurin KK, Mahadevia PJ. Healthcare costs within a year of respiratory syncytial virus among medicaid infants. Pediatr Pulmonol. 2010;45:772–81. doi:10.1002/ppul.21244.
   PubMed Web of Science ®Google Scholar
• Mosalli R, Alqarni SA, Khayyat WW, Alsaidi ST, Almatrafi AS, Bawakid AS, Paes B. Respiratory syncytial virus nosocomial outbreak in neonatal intensive care: a review of the incidence, management, and outcomes. Am J Infect Control. [Internet]. 2021. epub ahead of print. https://linkinghub.elsevier.com/retrieve/pii/S0196655321007112
   PubMed Web of Science ®Google Scholar
• Loubet P, Lenzi N, Valette M, Foulongne V, Krivine A, Houhou N, Lagathu G, Rogez S, Alain S, Duval X, et al. Clinical characteristics and outcome of respiratory syncytial virus infection among adults hospitalized with influenza-like illness in France. Clin Microbiol Infect. 2017;23(4):253–59. doi:10.1016/j.cmi.2016.11.014.
   PubMed Web of Science ®Google Scholar
• McLaurin KK, Farr AM, Wade SW, Diakun DR, Stewart DL. Respiratory syncytial virus hospitalization outcomes and costs of full-term and preterm infants. J Perinatol. 2016;36(11):990–96. doi:10.1038/jp.2016.113.
   PubMed Web of Science ®Google Scholar
• Rha B, Curns AT, Lively JY, Campbell AP, Englund JA, Boom JA, Azimi PH, Weinberg GA, Staat MA, Selvarangan R, et al. Respiratory syncytial virus-associated hospitalizations among young children: 2015-2016 [Internet]. 2020. http://publications.aap.org/pediatrics/article-pdf/146/1/e20193611/1081381/peds_20193611.pdf?casa_token=NEb8coMqaSwAAAAA:gOOjzURVbTwXJtDiOES1Dn6SX_Fpi0ONLwerBqwzm86dr4kkrutGDNTB2QJSEqsABfIP2HQ
   Google Scholar
• Arriola CS, Kim L, Langley G, Anderson EJ, Openo K, Martin AM, Lynfield R, Bye E, Como-Sabetti K, Reingold A, et al. Estimated burden of community-onset respiratory syncytial virus–associated hospitalizations among children aged <2 years in the United States. J Pediatric Infect Dis Soc. 2020;9(5):587–95. doi:10.1093/jpids/piz087.
   PubMed Web of Science ®Google Scholar
• Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, Anderson LJ, Fukuda K. Mortality associated with influenza and respiratory syncytial virus in the United States. Jama. [Internet] Available from. 2003;289(2):179–86.
   PubMed Web of Science ®Google Scholar
• Bergeron HC, Tripp RA. Emerging small and large molecule therapeutics for respiratory syncytial virus. Expert Opin Investig Drugs. 2020;29(3):285–94. doi:10.1080/13543784.2020.1735349.
   PubMed Web of Science ®Google Scholar
• Hatter L, Eathorne A, Hills T, Bruce P, Beasley R. Respiratory syncytial virus: paying the immunity debt with interest. Lancet Child Adolesc Health. 2021;5(12):e44–5. doi:10.1016/S2352-4642(21)00333-3.
   PubMedGoogle Scholar
• di Mattia G, Nenna R, Mancino E, Rizzo V, Pierangeli A, Villani A, Midulla F. During the COVID-19 pandemic where has respiratory syncytial virus gone? Pediatr Pulmonol. 2021;56(10):3106–09. doi:10.1002/ppul.25582.
   PubMed Web of Science ®Google Scholar
• Mejias A, Rodríguez-Fernández R, Oliva S, Peeples ME, Ramilo O. The journey to a respiratory syncytial virus vaccine. Ann Allergy Asthma Immunol. 2020;125(1):36–46. doi:10.1016/j.anai.2020.03.017.
   PubMed Web of Science ®Google Scholar
• Lively JY, Curns AT, Weinberg GY, Edwards KM, Staat MA, Prill MM, Gerber SI, Lengley GE. Respiratory syncytial virus–associated outpatient visits among children younger than 24 months. J Pediatric Infect Dis Soc. 2019;8(3):284. doi:10.1093/jpids/piz011.
   PubMed Web of Science ®Google Scholar
• Rainisch G, Adhikari B, Meltzer MI, Langley G. Estimating the impact of multiple immunization products on medically-attended respiratory syncytial virus (RSV) infections in infants. Vaccine. 2020;38(2):251–57. doi:10.1016/j.vaccine.2019.10.023.
   PubMed Web of Science ®Google Scholar
• Tramuto F, Maida CM, di Naro D, Randazzo G, Vitale F, Restivo V, Costantino C, Amodio E, Casuccio A, Graziano G, et al. Respiratory syncytial virus: new challenges for molecular epidemiology surveillance and vaccination strategy in patients with ILI/SARI. Vaccines (Basel). 2021;9(11):1334. doi:10.3390/vaccines9111334.
   PubMed Web of Science ®Google Scholar
• Griffiths C, Drews SJ, Marchant DJ. Respiratory syncytial virus: infection, detection, and new options for prevention and treatment. Clin Microbiol Rev. 2017;30(1):277–319. doi:10.1128/CMR.00010-16.
   PubMed Web of Science ®Google Scholar
• Sullender WM. Respiratory syncytial virus genetic and antigenic diversity. 2000.
   Google Scholar
• Mastrangelo P, Chin AA, Tan S, Jeon AH, Ackerley CA, Siu KK, Lee JE, Hegele RG. Identification of RSV fusion protein interaction domains on the virus receptor, nucleolin. Viruses. 2021;13(2):261. doi:10.3390/v13020261.
   PubMed Web of Science ®Google Scholar
• Battles MB, McLellan JS. Respiratory syncytial virus entry and how to block it. Nat Rev Microbiol. 2019;17(4):233–45. doi:10.1038/s41579-019-0149-x.
   PubMed Web of Science ®Google Scholar
• San-Juan-Vergara H, Peeples ME. Importance of virus characteristics in respiratory syncytial virus-induced disease. Immunol Allergy Clin North Am. 2019;39(3):321–34. doi:10.1016/j.iac.2019.04.001.
   PubMed Web of Science ®Google Scholar
• Weber A, Weber M, Milligan P. Modeling epidemics caused by respiratory syncytial virus (RSV). Math Biosci [Internet]. 2001;172(2):95–113. www.elsevier.com/locate/mbsMathematicalBiosciences172
   PubMed Web of Science ®Google Scholar
• Feng Z, Xu L, Xie Z. Receptors for respiratory syncytial virus infection and host factors regulating the life cycle of respiratory syncytial virus. Front Cell Infect Microbiol [Internet]. 2022;12. https://www.frontiersin.org/articles/10.3389/fcimb.2022.858629/full
   Web of Science ®Google Scholar
• King T, Mejias A, Ramilo O, Peeples ME, Pietschmann T. The larger attachment glycoprotein of respiratory syncytial virus produced in primary human bronchial epithelial cultures reduces infectivity for cell lines. PLoS Pathog. 2021;17(4):e1009469. doi:10.1371/journal.ppat.1009469.
   PubMed Web of Science ®Google Scholar
• Tripp RA, Jones LP, Haynes LM, Zheng H, Murphy PM, Anderson LJ. CX3C chemokine mimicry by respiratory syncytial virus G glycoprotein. Nature Immunology [Internet]. 2001;2(8):732–38. http://immunol.nature.com
   PubMed Web of Science ®Google Scholar
• Pinto RA, Arredondo SM, Bono MR, Gaggero AA, Díaz PV. T helper 1/T helper 2 cytokine imbalance in respiratory syncytial virus infection is associated with increased endogenous plasma cortisol. Pediatrics. 2006;117(5):117. doi:10.1542/peds.2005-2119.
   PubMed Web of Science ®Google Scholar
• Russell CD, Unger SA, Walton M, Schwarze J. The human immune response to respiratory syncytial virus infection. Clin Microbiol Rev. 2017;30(2):481–502. doi:10.1128/CMR.00090-16.
   PubMed Web of Science ®Google Scholar
• Kombe IK, Agoti CN, Munywoki PK, Baguelin M, Nokes DJ, Medley GF. Integrating epidemiological and genetic data with different sampling intensities into a dynamic model of respiratory syncytial virus transmission. Sci Rep. 2021;11(1):11. doi:10.1038/s41598-021-81078-x.
   PubMed Web of Science ®Google Scholar
• Piedimonte G, Perez MK. Respiratory syncytial virus infection and bronchiolitis practice gaps. Pediatr Rev. 2014;35(12):519–30. doi:10.1542/pir.35.12.519.
   PubMedGoogle Scholar
• Biagi C, Dondi A, Scarpini S, Rocca A, Vandini S, Poletti G, Lanari M. Current state and challenges in developing respiratory syncytial virus vaccines. Vaccines (Basel). 2020;8(4):672. doi:10.3390/vaccines8040672.
   PubMed Web of Science ®Google Scholar
• Tognarelli EI, Bueno SM, González PA. Immune-Modulation by the human respiratory syncytial virus: focus on dendritic cells. Front Immunol. 2019;10. doi:10.3389/fimmu.2019.00810.
   PubMed Web of Science ®Google Scholar
• Graham BS. Vaccine development for respiratory syncytial virus. Curr Opin Virol. 2017;23:107–12. doi:10.1016/j.coviro.2017.03.012.
   PubMed Web of Science ®Google Scholar
• Graham BS, Modjarrad K, McLellan JS. Novel antigens for RSV vaccines. Curr Opin Immunol. 2015;35:30–38. doi:10.1016/j.coi.2015.04.005.
   PubMed Web of Science ®Google Scholar
• Maruz NI, Horsley NM, Englund JA, Nederend M, Magaret A, Kumar A, Jacobino SR, de Haan CAM, Khatry SK, LeClerq SC, et al. Breast milk prefusion F IgG as a correlate of protection against respiratory syncytial virus acute respiratory illness. J Infect Dis. 2019;219(1):59–67. doi:10.1093/infdis/jiy477.
   PubMed Web of Science ®Google Scholar
• Kulkarni PS, Hurwitz JL, Simões EAF, Piedra PA. Establishing correlates of protection for vaccine development: considerations for the respiratory syncytial virus vaccine field. Viral Immunol. 2018;31(2):195–203. doi:10.1089/vim.2017.0147.
   PubMed Web of Science ®Google Scholar
• Rossey I, McLellan JS, Saelens X, Schepens B. Clinical potential of prefusion RSV F-specific antibodies. Trends Microbiol. 2018;26(3):209–19. doi:10.1016/j.tim.2017.09.009.
   PubMed Web of Science ®Google Scholar
• Patel N, Massare MJ, Tian JH, Guebre-Xabier M, Lu H, Zhou H, Maynard E, Scott D, Ellingsworth L, Glenn G, et al. Respiratory syncytial virus prefusogenic fusion (F) protein nanoparticle vaccine: structure, antigenic profile, immunogenicity, and protection. Vaccine. 2019;37(41):6112–24. doi:10.1016/j.vaccine.2019.07.089.
   PubMed Web of Science ®Google Scholar
• Tayyari F, Marchant D, Moraes TJ, Duan W, Mastrangelo P, Hegele RG. Identification of nucleolin as a cellular receptor for human respiratory syncytial virus. Nat Med. 2011;17(9):1132–35. doi:10.1038/nm.2444.
   PubMed Web of Science ®Google Scholar
• Weiner JH. Respiratory syncytial virus infection and palivizumab: are families receiving accurate information? Am J Perinatol. 2010;27(3):219–23. doi:10.1055/s-0029-1239493.
   PubMed Web of Science ®Google Scholar
• Kishko M, Catalan J, Swanson K, DiNapoli J, Wei CJ, Delagrave S, Chivukula S, Zhang L. Evaluation of the respiratory syncytial virus G-directed neutralizing antibody response in the human airway epithelial cell model. Virology. 2020;550:21–26. doi:10.1016/j.virol.2020.08.006.
   PubMed Web of Science ®Google Scholar
• Fedechkin SO, George NL, Wolff JT, Kauvar LM, Dubois RM Structures of respiratory syncytial virus G antigen bound to broadly neutralizing antibodies [Internet]. 2018. http://immunology.sciencemag.org/
   Google Scholar
• Pica N, Bouvier NM. Environmental factors affecting the transmission of respiratory viruses. Curr Opin Virol. 2012;2(1):90–95. doi:10.1016/j.coviro.2011.12.003.
   PubMed Web of Science ®Google Scholar
• Taleb SA, Al-Ansari K, Nasrallah GK, Elrayess MA, Al-Thani AA, Derrien-Colemyn A, Ruckwardt TJ, Graham BS, Yassine HM. Level of maternal respiratory syncytial virus (RSV) F antibodies in hospitalized children and correlates of protection. Int J Infect Dis. 2021;109:56–62. doi:10.1016/j.ijid.2021.06.015.
   PubMed Web of Science ®Google Scholar
• Nourbakhsh S, Shoukat A, Zhang K, Poliquin G, Halperin D, Sheffield H, Halperin SA, Langley JM, Moghadas SM. Effectiveness and cost-effectiveness of RSV infant and maternal immunization programs: a case study of Nunavik, Canada. eClinicalMedicine. 2021;41:101141. doi:10.1016/j.eclinm.2021.101141.
   PubMedGoogle Scholar
• Buchwald AG, Graham BS, Traore A, Haidara FC, Chen M, Morabito K, Lin BC, Sow SO, Levine MM, Pasetti MF, et al. Respiratory Syncytial Virus (RSV) neutralizing antibodies at birth predict protection from RSV illness in infants in the first 3 months of life. Clin Infect Dis. 2021;73(11):e4421–7. doi:10.1093/cid/ciaa648.
   PubMed Web of Science ®Google Scholar
• Jacoby P, Glass K, Moore HC. Characterizing the risk of respiratory syncytial virus in infants with older siblings: a population-based birth cohort study. Epidemiol Infect. 2017;145(2):266–71. doi:10.1017/S0950268816002545.
   PubMed Web of Science ®Google Scholar
• Gabutti G, Azzari C, Bonanni P, Prato R, Tozzi AE, Zanetti A, Zuccotti G. Pertussis. Hum Vaccin Immunother [Internet]. 2015;11(1):108–17. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4514233&tool=pmcentrez&rendertype=abstract
   PubMed Web of Science ®Google Scholar
• Meregaglia M, Ferrara L, Melegaro A, Demicheli V. Parent “cocoon” immunization to prevent pertussis-related hospitalization in infants: the case of Piemonte in Italy. Vaccine [Internet]. 2013;31(8):1135–37. doi:http://dx.doi.org/10.1016/j.vaccine.2012.12.061.
   PubMed Web of Science ®Google Scholar
• Esposito S, Principi N. Prevention of pertussis: an unresolved problem. Human Vaccines Immunother. [Internet]. 2018;5515:1–27. https://www.tandfonline.com/doi/full/10.1080/21645515.2018.1480298
   Google Scholar
• Riccò M, Vezzosi L, Gualerzi G, Bragazzi NL, Balzarini F Pertussis immunization in healthcare workers working in pediatric settings: knowledge, attitudes and practices (KAP) of occupational physicians. Preliminary results from a web-based survey (2017). J Prev Med Hyg 2020:19–21.
   Google Scholar
• Reis J, Shaman J. Simulation of four respiratory viruses and inference of epidemiological parameters. Infect Dis Model. 2018;3:23–34. doi:10.1016/j.idm.2018.03.006.
   PubMedGoogle Scholar
• Reis J, Shaman J, Wilke CO. Retrospective parameter estimation and forecast of respiratory syncytial virus in the United States. PLoS Comput Biol. 2016;12(10):e1005133. doi:10.1371/journal.pcbi.1005133.
   PubMed Web of Science ®Google Scholar
• Byington CL, Wilkes J, Korgenski K, Sheng X. Respiratory syncytial virus–associated mortality in hospitalized infants and young children. Pediatrics. 2015;135(1):e24–31. doi:10.1542/peds.2014-2151.
   PubMed Web of Science ®Google Scholar
• Berbers G, Mollema L, van der Klis F, den Hartog G, Schepp R. Antibody responses to respiratory syncytial virus: a cross-sectional serosurveillance study in the Dutch population focusing on infants younger than 2 years. J Infect Dis. 2021;224(2):269–78. doi:10.1093/infdis/jiaa483.
   PubMed Web of Science ®Google Scholar
• Suleiman-Martos N, Caballero-Vázquez A, Gómez-Urquiza JL, Albendín-García L, Romero-Béjar JL, Cañadas-De la Fuente GA. Prevalence and risk factors of respiratory syncytial virus in children under 5 years of age in the who European region: a systematic review and meta-analysis. J Pers Med. 2021;11(5):416. doi:10.3390/jpm11050416.
   PubMed Web of Science ®Google Scholar
• Cusi MG, Terrosi C, Kleines M, Schildgen O. RSV and HMPV seroprevalence in Tuscany (Italy) and North-Rhine Westfalia (Germany) in the winter season 2009/2010. Influenza Other Respir Viruses. 2011;5(6):380–81. doi:10.1111/j.1750-2659.2011.00252.x.
   PubMed Web of Science ®Google Scholar
• Haynes AK, Prill MM, Iwane MK, Gerber SI. Respiratory syncytial virus—United States, July 2012–June 2014. Morb Mortl Wkly Rep MMWR [Internet]. 2014;63:1133–36. http://www.cdc.gov/surveillance/nrevss
   PubMed Web of Science ®Google Scholar
• Rose EB, Wheatley A, Langley G, Gerber S, Haynes A. Respiratory syncytial virus seasonality — United States, 2014–2017. Morb Mortal Wkly Rep. 2018;67(2):71–76. doi:10.15585/mmwr.mm6702a4.
   PubMed Web of Science ®Google Scholar
• Kenmoe S, Bigna JJ, Well EA, Simo FBN, Penlap VB, Vabret A, Njouom R. Prevalence of human respiratory syncytial virus infection in people with acute respiratory tract infections in Africa: a systematic review and meta-analysis. Influenza Other Respir Viruses. 2018;12(6):793–803. doi:10.1111/irv.12584.
   PubMed Web of Science ®Google Scholar
• Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE Respiratory syncytial virus infection in elderly and high-risk adults [Internet]. 2005. doi:10.1056/NEJMoa043951.
   Google Scholar
• Shi T, Arnott A, Semogas I, Falsey AR, Openshaw P, Wedzicha JA, Campbell H, Nair H, Nair H, Campbell H. The etiological role of common respiratory viruses in acute respiratory infections in older adults: a systematic review and meta-analysis. J Infect Dis. 2020;222(Supplement_7):S563–9. doi:10.1093/infdis/jiy662.
   PubMedGoogle Scholar
• Choi Y, Hill-Ricciuti A, Branche AR, Sieling WD, Saiman L, Walsh EE, Phillips M, Falsey AR, Finelli L. Cost determinants among adults hospitalized with respiratory syncytial virus in the United States, 2017-2019. Influenza Other Respir Viruses. 2021;16(1):151–58. doi:10.1111/irv.12912.
   PubMedGoogle Scholar
• Paes BA Mitchell I Banerji A Lanctôt KL, Langley JM. A decade of respiratory syncytial virus epidemiology and prophylaxis: translating evidence into everyday clinical practice case presentation. Can Respir J. 2011;18(2):e10–e19. doi:10.1155/2011/493056.
   PubMed Web of Science ®Google Scholar
• Auvinen R, Syrjänen R, Ollgren J, Nohynek H, Skogberg K. Clinical characteristics and population-based attack rates of respiratory syncytial virus versus influenza hospitalizations among adults-an observational study. Influenza Other Respir Viruses. Onlineahead of print. 2021;16(2):276–88. doi:10.1111/irv.12914.
   PubMed Web of Science ®Google Scholar
• Hall CB, Long CE, Schnabel KC. Respiratory syncytial virus infections in previously healthy working adults. Clin Infect Dis [Internet]. 2001;33(6):792–96.
   PubMed Web of Science ®Google Scholar
• Calderaro A, de Conto F, Buttrini M, Piccolo G, Montecchini S, Maccari C, Martinelli M, di Maio A, Ferraglia F, Pinardi F, et al. Human respiratory viruses, including SARS-CoV-2, circulating in the winter season 2019–2020 in Parma, Northern Italy. Int J Infect Dis. 2021;102:79–84. doi:10.1016/j.ijid.2020.09.1473.
   PubMed Web of Science ®Google Scholar
• Sherman AC, Babiker A, Sieben AJ, Pyden A, Steinberg J, Kraft CS, Koelle K, Kanjilal S. The effect of severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) mitigation strategies on seasonal respiratory viruses: a tale of 2 large metropolitan centers in the United States. Clin Infect Dis. 2021;72(5):E154–7. doi:10.1093/cid/ciaa1704.
   PubMed Web of Science ®Google Scholar
• Kuitunen I, Artama M, Mäkelä L, Backman K, Heiskanen-Kosma T, Renko M. Effect of social distancing due to the COVID-19 pandemic on the incidence of viral respiratory tract infections in children in Finland during early 2020. Pediatr Infect Dis J. 2020;39(12):E423–7. doi:10.1097/INF.0000000000002845.
   PubMed Web of Science ®Google Scholar
• van Brusselen D, de Troeyer K, Ter Haar E, Vander Auwera A, Poschet K, van Nuijs S, Bael A, Stobbelaar K, Verhulst S, van Herendael B, et al. Bronchiolitis in COVID-19 times: a nearly absent disease? Eur J Pediatr [Internet]. 2021;180(6):1969–73. https://www.cdc.gov/coronavirus/2019-ncov/more/
   PubMed Web of Science ®Google Scholar
• Britton PN, Hu N, Saravanos G, Shrapnel J, Davis J, Snelling T, Dalby-Payne J, Kesson AM, Wood N, Macartney K, et al. COVID-19 public health measures and respiratory syncytial virus. Lancet Child Adolesc Health. 2020;4(11):e42–3. doi:10.1016/S2352-4642(20)30307-2.
   PubMedGoogle Scholar
• Foley DA, Phuong LK, Peplinski J, Lim SM, Lee WH, Farhat A, Minney-SmithCA, Martin AC, Mace AO, Sikazwe CT, et al. Examining the interseasonal resurgence of respiratory syncytial virus in Western Australia. Arch Dis Child. 2022 Mar;107(3):e7. doi:10.1136/archdischild-2021-322507.
   PubMed Web of Science ®Google Scholar
• Foley DA, Yeoh DK, Minney-Smith CA, Martin AC, Mace AO, Sikazwe CT, Le H, Levy A, Moore HC, Blyth CC. The interseasonal resurgence of respiratory syncytial virus in Australian children following the reduction of coronavirus disease 2019–related public health measures. Clin Infect Dis. 2021;73(9):E2829–30. doi:10.1093/cid/ciaa1906.
   PubMedGoogle Scholar
• Varela FH, Scotta MC, Polese-Bonatto M, Sartor ITS, Ferreira CF, Fernandes IR, Zavaglia GO, de Almeida WAF, Arakaki-Sanchez D, Pinto LA, et al. Absence of detection of RSV and influenza during the COVID-19 pandemic in a Brazilian cohort: likely role of lower transmission in the community. J Glob Health. 2021;11:05007. doi:10.7189/jogh.11.05007.
   PubMed Web of Science ®Google Scholar
• Ippolito G, la Vecchia A, Umbrello G, di Pietro G, Bono P, Scalia S, Pinzani R, Tagliabue C, Bosis S, Agostoni C, et al. Disappearance of seasonal respiratory viruses in children under two years old during COVID-19 pandemic: a monocentric retrospective study in Milan, Italy. Front Pediatr. 2021;9:721005. doi:10.3389/fped.2021.721005.
   PubMed Web of Science ®Google Scholar
• Ujiie M, Tsuzuki S, Nakamoto T, Iwamoto N, Ujiie M. Resurgence of respiratory syncytial virus infections during COVID-19 pandemic, Tokyo, Japan. Emerg Infect Dis. 2021;27(11):2969–70. doi:10.3201/eid2711.211565.
   PubMed Web of Science ®Google Scholar
• Lumley SF, Richens N, Lees E, Cregan J, Kalimeris E, Oakley S, Morgan M, Segal S, Dawson M, Walker AS, et al. Changes in paediatric respiratory infections at a UK teaching hospital 2016-2021; impact of the SARS-CoV-2 pandemic. J Infect [Internet]. 2021. https://linkinghub.elsevier.com/retrieve/pii/S0163445321005405
   Web of Science ®Google Scholar
• Taylor A, Whittaker E. The changing epidemiology of respiratory viruses in children during the COVID-19 pandemic: a canary in a COVID time. Pediatr Infect Dis J. 2022;41(2):E46–8. doi:10.1097/INF.0000000000003396.
   PubMed Web of Science ®Google Scholar
• Li Y, Wang X, Cong B, Deng S, Feikin DR, Nair H Understanding the potential drivers for respiratory syncytial virus rebound during the COVID-19 pandemic.
   Google Scholar
• Sánchez Luna M, Manzoni P, Paes B, Baraldi E, Cossey V, Kugelman A, Chawla R, Dotta A, Rodríguez Fernández R, Resch B, et al. Expert consensus on Palivizumab use for respiratory syncytial virus in developed countries. Paediatr Respir Rev. 2020;33:35–44. doi:10.1016/j.prrv.2018.12.001.
   PubMed Web of Science ®Google Scholar
• Bloomfield A, DeVincenzo JP, Ambrose CS, Krilov LR. RSV and non-RSV illness hospitalization in RSV immunoprophylaxis recipients: a systematic literature review. J Clin Virol. 2020;129:104339. doi:10.1016/j.jcv.2020.104339.
   PubMed Web of Science ®Google Scholar
• Rocca A, Biagi C, Scarpini S, Dondi A, Vandini S, Pierantoni L, Lanari M. Passive immunoprophylaxis against respiratory syncytial virus in children: where are we now? Int J Mol Sci. 2021;22(7):3703. doi:10.3390/ijms22073703.
   PubMed Web of Science ®Google Scholar
• Griffin MP, Yuan Y, Takas T, Domachowske JB, Madhi SA, Manzoni P, Simões EAF, Esser MT, Khan AA, Dubovsky F, et al. Single-Dose Nirsevimab for prevention of RSV in preterm infants. N Engl J Med. 2020;383(5):415–25. doi:10.1056/NEJMoa1913556.
   PubMed Web of Science ®Google Scholar
• Shan J, Britton PN, King CL, Booy R. The immunogenicity and safety of respiratory syncytial virus vaccines in development: a systematic review. Influenza Other Respir Viruses. 2021;15(4):539–51. doi:10.1111/irv.12850.
   PubMed Web of Science ®Google Scholar
• World Health Organization (WHO). WHO preferred product characteristics for respiratory syncytial virus (RSV) vaccines [Internet]. Geneva; 2017. http://apps.who.int/bookorders
   Google Scholar
• Gunatilaka A, Giles ML. Maternal RSV vaccine development. Where to from here? Hum Vaccin Immunother. 2021;17(11):4542–48. doi:10.1080/21645515.2021.1955608.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. A trial to evaluate the efficacy and safety of RSVpreF in infants born to women vaccinated during pregnancy. 2022.
   Google Scholar
• ClinicalTrials.gov. A phase III double-blind study to assess safety and efficacy of an RSV maternal unadjuvanted vaccine, in pregnant women and infants born to vaccinated mothers (GRACE). [Internet]. 2022. https://clinicaltrials.gov/ct2/show/NCT04605159?type=Intr&cond=rsv&phase=2&draw=2
   Google Scholar
• Engmann C, Fleming JA, Khan S, Innis BL, Smith JM, Hombach J, Sobanjo-Ter Meulen A. Closer and closer? Maternal immunization: current promise, future horizons. Journal of Perinatology. 2020;40(6):844–57. doi:10.1038/s41372-020-0668-3.
   PubMed Web of Science ®Google Scholar
• Madhi SA, Polack FP, Piedra PA, Munoz FM, Trenholme AA, Simões EAF, Swamy GK, Agrawal S, Ahmed K, August A, et al. Respiratory syncytial virus vaccination during pregnancy and effects in infants. N Engl J Med. 2020;383(5):426–39. doi:10.1056/NEJMoa1908380.
   PubMed Web of Science ®Google Scholar
• Lewnard JA, Fries LF, Cho I, Chen J, Laxminarayan R. Prevention of antimicrobial prescribing among infants following maternal vaccination against respiratory syncytial virus. Proc Natl Acad Sci. 2022;119(12):e2112410119. doi:10.1073/pnas.2112410119.
   PubMed Web of Science ®Google Scholar
• Phijffer EWEM, Bont LJ. Are we ready for maternal respiratory syncytial virus vaccination? J Infect Dis. 2021. doi:10.1093/infdis/jiab613.
   Web of Science ®Google Scholar
• Walsh EE, Falsey AR, Scott DA, Gurtman A, Zareba AM, Jansen KU, Gruber WC, Dormitzer PR, Swanson KA, Radley D , et al. A randomized phase 1/2 study of a respiratory syncytial virus prefusion F vaccine. J Infect Dis. 2022 Apr 19;225(8):1357–1366. doi:10.1093/infdis/jiab612.
   PubMed Web of Science ®Google Scholar
• Scheltema NM, Kavelaars XM, Thorburn K, Hennus MP, van Woensel JB, van der Ent CK, Borghans JAM, Bont LJ, Drylewicz J, van Woensel JB, van der Ent CK. Potential impact of maternal vaccination on life-threatening respiratory syncytial virus infection during infancy. Vaccine. 2018;36(31):4693–700. doi:10.1016/j.vaccine.2018.06.021.
   PubMed Web of Science ®Google Scholar
• Amirthalingam G, Andrews N, Campbell H, Ribeiro S, Kara E, Donegan K, Fry NK, Miller E, Ramsay M. Effectiveness of maternal pertussis vaccination in England: an observational study. The Lancet [Internet]. 2014;384(9953):1521–28. doi:10.1016/S0140-6736(14)60686-3.
   PubMed Web of Science ®Google Scholar
• Gkentzi D, Katsakiori P, Marangos M, Hsia Y, Amirthalingam G, Heath PT, Ladhani S. Maternal vaccination against pertussis: a systematic review of the recent literature. Arch Dis Child Fetal Neonatal Ed. 2017;102(5):F456–63. doi:10.1136/archdischild-2016-312341.
   PubMed Web of Science ®Google Scholar
• Fell DB, Bhutta ZA, Hutcheon JA, Karron RA, Knight M, Kramer MS, Monto AS, Swamy GK, Ortiz JR, Savitz DA. Report of the WHO technical consultation on the effect of maternal influenza and influenza vaccination on the developing fetus: Montreal, Canada, September 30–October 1, 2015. Vaccine. [Internet]. 2017;35(18):2279–87. doi:10.1016/j.vaccine.2017.03.056.
   PubMed Web of Science ®Google Scholar
• Walsh EE, Wang L, Falsey AR, Qiu X, Corbett A, Holden-Wiltse J, Mariani TJ, Topham DJ, Caserta MT. Virus-Specific antibody, viral load, and disease severity in respiratory syncytial virus infection. J Infect Dis. 2018;218(2):208–17. doi:10.1093/infdis/jiy106.
   PubMed Web of Science ®Google Scholar
• Groothuis JR, Simoes EA, Levin MJ, Hall CB, Long CE, Rodriguez WJ, Arrobio J, Meissner HC, Fulton DR, Welliver RC, et al. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. N Eng J Med. 1993;329(21):1524–30. doi:10.1056/NEJM199311183292102.
   PubMed Web of Science ®Google Scholar
• Glezen PW, Paredes A, Allison JE, Taber LH, Frank AL. Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level. J Pediatr. 1981;98(5):708–15. doi:10.1016/S0022-3476(81)80829-3.
   PubMed Web of Science ®Google Scholar
• Jans J, Wicht O, Widjaja I, Ahout IML, de Groot R, Guichelaar T, Luytjes W, de Jonge MI, de Haan CAM, Ferwerda G. Characteristics of RSV-specific maternal antibodies in plasma of hospitalized, acute RSV patients under three months of age. PLoS ONE. 2017;12(1):e0170877. doi:10.1371/journal.pone.0170877.
   PubMed Web of Science ®Google Scholar
• Chu HY, Newman KL, Englund JA, Cho S, Bull C, Lacombe K, Carlin K, Bulkow LR, Rudolph K, Debyle C, et al. Transplacental respiratory syncytial virus and influenza virus antibody transfer in Alaska native and Seattle Mother–Infant Pairs. J Pediatric Infect Dis Soc. 2021;10(3):230–36. doi:10.1093/jpids/piaa040.
   PubMed Web of Science ®Google Scholar
• Chu HY, Tielsch J, Katz J, Magaret AS, Khatry S, LeClerq SC, Shrestha L, Kuypers J, Steinhoff MC, Englund JA. Transplacental transfer of maternal respiratory syncytial virus (RSV) antibody and protection against RSV disease in infants in rural Nepal. Journal of Clinical Virology. 2017;95:90–95. doi:10.1016/j.jcv.2017.08.017.
   PubMed Web of Science ®Google Scholar
• Lloyd PC, May L, Hoffman D, Riegelman R, Simonsen L. The effect of birth month on the risk of respiratory syncytial virus hospitalization in the first year of life in the United States. Pediatr Infect Dis J. 2014;33(6):e135–40. doi:10.1097/INF.0000000000000250.
   PubMed Web of Science ®Google Scholar
• Yildiz M, Kara M, Sutcu M, Mese S, Demircili ME, Sivrikoz TS, Torun SH, Agacfidan A, Coban A, Unuvar E, et al. Evaluation of respiratory syncytial virus IgG antibody dynamics in mother-infant pairs cohort. Eur J Clin Microbiol Infect Dis. [Internet]. 2020;39(7):1279–86. doi:10.1007/s10096-020-03841-8.
   PubMed Web of Science ®Google Scholar
• Chu HY, Steinhoff MC, Magaret A, Zaman K, Roy E, Langdon G, Formica MA, Walsh EE, Englund JA. Respiratory syncytial virus transplacental antibody transfer and kinetics in Mother-Infant pairs in Bangladesh. J Infect Dis. 2014;210(10):1582–89. doi:10.1093/infdis/jiu316.
   PubMed Web of Science ®Google Scholar
• Wesumperuma HL, Pharoah POD, Hart CA, Hart CA. The influence of prematurity and low birthweight on transplacental antibody transfer in Sri Lanka. Ann Trop Med Parasitol. 1999;93(2):169–77. doi:10.1080/00034983.1999.11813407.
   PubMed Web of Science ®Google Scholar
• van den Berg JP, Westerbeek EAM, van der Klis FRM, Berbers GAM, van Elburg RM. Transplacental transport of IgG antibodies to preterm infants: a review of the literature. Early Hum Dev. 2011;87(2):67–72. doi:10.1016/j.earlhumdev.2010.11.003.
   PubMed Web of Science ®Google Scholar
• Okoko JB, Wesumperuma HL, Hart CA. The influence of prematurity and low birthweight on transplacental antibody transfer in a rural West African population. Trop Med Int Health. 2001;6(7):529–34. doi:10.1046/j.1365-3156.2001.00741.x.
   PubMed Web of Science ®Google Scholar
• Schwarz TF, Johnson C, Grigat C, Apter D, Csonka P, Lindblad N, Nguyen T-A, Gao FF, Qian H, Tullio AN, et al. Three dose levels of a maternal respiratory syncytial virus vaccine candidate are well tolerated and immunogenic in a randomized trial in nonpregnant women. J Infect Dis. 2021. doi:10.1093/infdis/jiab317.
   Web of Science ®Google Scholar
• Takashima MD, Grimwood K, Sly PD, Lambert SB, Chappell KJ, Watterson D, Young P, Kusel M, Holt B, Holt P, et al. Cord-Blood respiratory syncytial virus antibodies and respiratory health in first 5 years of life. Pediatr Pulmonol. 2021;56(12):3942–51. doi:10.1002/ppul.25688.
   PubMed Web of Science ®Google Scholar
• Koivisto K, Nieminen T, Mejias A, Capella Gonzalez C, Ye F, Mertz S, Peeples M, Ramilo O, Saxén H . Respiratory syncytial virus (RSV)–specific antibodies in pregnant women and subsequent risk of RSV hospitalization in young infants. J Infect Dis 2022 Apr 1;225(7): 1189–1196. doi:10.1093/infdis/jiab315.
   PubMed Web of Science ®Google Scholar
• Giles ML, Buttery J, Davey MA, Wallace E. Pregnant women’s knowledge and attitude to maternal vaccination including group B streptococcus and respiratory syncytial virus vaccines. Vaccine. 2019;37(44):6743–49. doi:10.1016/j.vaccine.2019.08.084.
   PubMed Web of Science ®Google Scholar
• Wheeler SM, Dotters-Katz S, Heine RP, Grotegut CA, Swamy GK. Maternal effects of respiratory syncytial virus infection during pregnancy. Emerg Infect Dis. 2015;21(11):1951–55. doi:10.3201/eid2111.150497.
   PubMed Web of Science ®Google Scholar
• Hause AM, Panagiotakopoulos L, Weintraub ES, Sy LS, Glenn SC, Tseng HF, McNeil MM. Adverse outcomes in pregnant women hospitalized with respiratory syncytial virus infection: a case series. Clin Infect Dis. 2021;72(1):138–40. doi:10.1093/cid/ciaa668.
   PubMed Web of Science ®Google Scholar
• Regan AK, Klein NP, Langley G, Drews SJ, Buchan S, Ball S, Kwong JC, Naleway A, Thompson M, Wyant BE, et al. Respiratory syncytial virus hospitalization during pregnancy in 4 high-income countries, 2010–2016. Clin Infect Dis. 2018;67(12):1915–18. doi:10.1093/cid/ciy439.
   PubMed Web of Science ®Google Scholar
• Madhi SA, Cutland CL, Downs S, Jones S, van Niekerk N, Simoes EAF, Nunes MC. Burden of respiratory syncytial virus infection in South African Human Immunodeficiency Virus (HIV)-infected and HIV-uninfected pregnant and postpartum women: a longitudinal cohort study. Clin Infect Dis. 2018;66(11):1658–65. doi:10.1093/cid/cix1088.
   PubMed Web of Science ®Google Scholar
• Wilcox CR, Calvert A, Metz J, Kilich E, Macleod R, Beadon K, Heath PT, Khalil A, Finn A, Snape MD, et al. Attitudes of pregnant women and healthcare professionals toward clinical trials and routine implementation of antenatal vaccination against respiratory syncytial virus: a multicenter questionnaire study. Pediatr Infect Dis J. 2019;38(9):944–51. doi:10.1097/INF.0000000000002384.
   PubMed Web of Science ®Google Scholar
• Bergeron HC, Tripp RA . Breakthrough therapy designation of nirsevimab for the prevention of lower respiratory tract illness caused by respiratory syncytial virus infections (RSV). Expert Opin Investig Drugs. 2022 Jan;31(1): 23–29. doi:10.1080/13543784.2022.2020248.
   PubMed Web of Science ®Google Scholar
• Hammitt LL, Dagan R, Yuan Y, Baca Cots M, Bosheva M, Madhi SA, Muller WJ, Zar HJ, Brooks D, Grenham A, et al. Nirsevimab for prevention of RSV in healthy late-preterm and term infants. New England J Med [Internet]. 2022;386(9):837–46. http://www.nejm.org/doi/10.1056/NEJMoa2110275
   PubMed Web of Science ®Google Scholar
• Domachowske J, Madhi SA, Simões EAF, Atanasova V, Cabañas F, Furuno K, Garcia-Garcia ML, Grantina I, Nguyen KA, Brooks D, et al. Safety of Nirsevimab for RSV in infants with heart or lung disease or prematurity. New England J Med [Internet]. 2022;386(9):892–94. http://www.nejm.org/doi/10.1056/NEJMc2112186
   PubMed Web of Science ®Google Scholar
• Li X, Bilcke J, Vázquez Fernández L, Bont L, Willem L, Wisløff T, Jit M, Beutels P, Beutels P, Bont L, et al. Cost-Effectiveness of respiratory syncytial virus disease prevention strategies: maternal vaccine versus seasonal or year-round monoclonal antibody program in Norwegian children. J Infect Dis [Internet]. 2022. https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiac064/6549175
   Web of Science ®Google Scholar
• Ananworanich J, Heaton PM. Bringing preventive RSV monoclonal antibodies to infants in low- and middle-income countries: challenges and opportunities. Vaccines (Basel). 2021;9(9). doi:10.3390/vaccines9090961.
   PubMed Web of Science ®Google Scholar
• Sparrow, E, Adetifa, I, Chaiyakunapruk, N, Cherian, T, Fell, DB, Graham, BS, Innis, B, Kaslow, DC, Karron, RA, Nair, H et al . WHO preferred product characteristics for monoclonal antibodies for passive immunization against respiratory syncytial virus (RSV) disease in infants - Key considerations for global use. Vaccine. Geneva;2022 Feb 17:S0264-410X(22)00186-4. doi:10.1016/j.vaccine.2022.02.040
   Google Scholar
• Lorcy A, Gilca R, Dubé E, Rochette M, de Serres G. Feasibility and ethical issues: experiences and concerns of healthcare workers regarding a new RSV prophylaxis programme in Nunavik, Quebec. Int J Circumpolar Health. 2020;79(1). doi:10.1080/22423982.2020.1742564.
   PubMed Web of Science ®Google Scholar
• Frogel MP, Stewart DL, Hoopes M, Fernandes AW, Mahadevia PJ. A systematic review of compliance with Palivizumab Administration for RSV immunoprophylaxis. J Managed Care Pharm [Internet]. 2010;16(1):46–58. www.amcp.org.
   Google Scholar
• Langedijk AC, Harding ER, Konya B, Vrancken B, Lebbink RJ, Evers A, Willemsen J, Lemey P, Bont LJ. A systematic review on global RSV genetic data: identification of knowledge gaps. Rev Med Virol. 2021. doi:10.1002/rmv.2284.
   PubMed Web of Science ®Google Scholar
• Anderson LJ, Jadhao SJ, Paden CR, Tong S. Functional features of the respiratory syncytial virus G protein. Viruses. 2021;13(7):1214. doi:10.3390/v13071214.
   PubMed Web of Science ®Google Scholar
• Esposito S, Scarselli E, Lelii M, Scala A, Vitelli A, Capone S, Fornili M, Biganzoli E, Orenti A, Nicosia A, et al. Antibody response to respiratory syncytial virus infection in children <18 months old. Hum Vaccin Immunother. 2016;12(7):1700–06. doi:10.1080/21645515.2016.1145847.
   PubMed Web of Science ®Google Scholar
• Hall CB, Weinberg GA, Blumkin AK, Edwards KM, Staat MA, Schultz AF, Poehling KA, Szilagyi PG, Griffin MR, Williams JV, et al. Respiratory syncytial virus–associated hospitalizations among children less than 24 months of age. Pediatrics. 2013;132(2):e341–8. doi:10.1542/peds.2013-0303.
   PubMed Web of Science ®Google Scholar
• Domachowske JB, Anderson EJ, Goldstein M. The future of respiratory syncytial virus disease prevention and treatment. Infect Dis Ther. 2021;10(S1):47–60. doi:10.1007/s40121-020-00383-6.
   PubMedGoogle Scholar
• Aliprantis AO, Shaw CA, Griffin P, Farinola N, Railkar RA, Cao X, Liu W, Sachs JR, Swenson CJ, Lee H, et al. A phase 1, randomized, placebo-controlled study to evaluate the safety and immunogenicity of an mRNA-based RSV prefusion F protein vaccine in healthy younger and older adults. Hum Vaccine Immunother. 2021;17(5):1248–61. doi:10.1080/21645515.2020.1829899.
   PubMed Web of Science ®Google Scholar
• Staadegaard L, Caini S, Wangchuk S, Thapa B, de Almeida WAF, de Carvalho FC, Njouom R, Fasce RA, Bustos P, Kyncl J, et al. The global epidemiology of RSV in community and hospitalized care: findings from 15 countries. Open Forum Infect Dis. 2021;8(7):ofab159. doi:10.1093/ofid/ofab159.
   PubMed Web of Science ®Google Scholar
• Lanari M, Anderson EJ, Sheridan-Pereira M, Carbonell-Estrany X, Paes B, Rodgers-Gray BS, Fullarton JR, Grubb E, Blanken M. Burden of respiratory syncytial virus hospitalisation among infants born at 32-35 weeks’ gestational age in the Northern Hemisphere: pooled analysis of seven studies. Epidemiol Infect. 2020;148:e170. doi:10.1017/S0950268820001661.
   PubMed Web of Science ®Google Scholar
• Halabi KC, Saiman L, Zachariah P. The epidemiology of respiratory syncytial virus in New York City during the COVID-19 pandemic compared with previous years. J Pediatr. 2022;242:242–44. doi:10.1016/j.jpeds.2021.10.057.
   PubMed Web of Science ®Google Scholar
• Seale H, Dyer CEF, Abdi I, Rahman KM, Sun Y, Qureshi MO, Dowell-Day A, Sward J, Islam MS. Improving the impact of non-pharmaceutical interventions during COVID-19: examining the factors that influence engagement and the impact on individuals. BMC Infect Dis. 2020;20(1):20. doi:10.1186/s12879-020-05340-9.
   PubMed Web of Science ®Google Scholar
• Hall CB, Walsh EE, Long CE, Schnabel KC. Immunity to and frequency of reinfection with respiratory syncytial virus. J Infect Dis. 1991;163(4):693–98. doi:10.1093/infdis/163.4.693.
   PubMed Web of Science ®Google Scholar
• Buchy P, Badur S, Kassianos G, Preiss S, Tam JS. Vaccinating pregnant women against influenza needs to be a priority for all countries: an expert commentary. Int J Infect Dis. 2020;92:1–12. doi:10.1016/j.ijid.2019.12.019.
   PubMed Web of Science ®Google Scholar
• Baïssas T, Boisnard F, Cuesta Esteve I, Garcia Sánchez M, Jones CE, Rigoine de Fougerolles T, Tan L, Vitoux O, Klein C. Vaccination in pregnancy against pertussis and seasonal influenza: key learnings and components from high-performing vaccine programmes in three countries: the United Kingdom, the United States and Spain. BMC Public Health. 2021;21(1). doi:10.1186/s12889-021-12198-2.
   PubMed Web of Science ®Google Scholar
• Zylbersztejn A, Almossawi O, Gudka N, Tompsett D, de Stavola B, Standing JF, Smyth R, Hardelid P. Access to palivizumab among children at high risk of respiratory syncytial virus complications in English hospitals. Br J Clin Pharmacol. 2022;88(3):1246–57. doi:10.1111/bcp.15069.
   PubMed Web of Science ®Google Scholar
• Chida-Nagai A, Sato H, Sato I, Shiraishi M, Sasaki D, Izumi G, Yamazawa H, Cho K, Manabe A, Takeda A. Risk factors for hospitalisation due to respiratory syncytial virus infection in children receiving prophylactic palivizumab. Eur J Pediatr. 2022;181(2):539–47. doi:10.1007/s00431-021-04216-7.
   PubMed Web of Science ®Google Scholar
• Viguria N, Navascués A, Juanbeltz R, Echeverría A, Ezpeleta C, Castilla J. Effectiveness of palivizumab in preventing respiratory syncytial virus infection in high-risk children. Hum Vaccin Immunother. 2021;17(6):1867–72. doi:10.1080/21645515.2020.1843336.
   PubMed Web of Science ®Google Scholar
• Rossey I, Saelens X. Vaccines against human respiratory syncytial virus in clinical trials, where are we now? Expert Rev Vaccines. 2019;18(10):1053–67. doi:10.1080/14760584.2019.1675520.
   PubMed Web of Science ®Google Scholar